Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article (Journal Article)

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

Full Text

Duke Authors

Cited Authors

  • Greenberg, PL; Stone, RM; Al-Kali, A; Barta, SK; Bejar, R; Bennett, JM; Carraway, H; De Castro, CM; Deeg, HJ; DeZern, AE; Fathi, AT; Frankfurt, O; Gaensler, K; Garcia-Manero, G; Griffiths, EA; Head, D; Horsfall, R; Johnson, RA; Juckett, M; Klimek, VM; Komrokji, R; Kujawski, LA; Maness, LJ; O'Donnell, MR; Pollyea, DA; Shami, PJ; Stein, BL; Walker, AR; Westervelt, P; Zeidan, A; Shead, DA; Smith, C

Published Date

  • January 2017

Published In

Volume / Issue

  • 15 / 1

Start / End Page

  • 60 - 87

PubMed ID

  • 28040720

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.0007


  • eng

Conference Location

  • United States